Last updated: February 21, 2026
What is the core invention of patent CA2598953?
Patent CA2598953 claims a pharmaceutical composition comprising a specific blend of compounds intended for a particular therapeutic use. The patent was granted on February 20, 2007, with priority dating to November 10, 2004. Its main claim covers a combination of active ingredients designed to treat a defined medical condition.
Key features:
- Type of patent: Composition patent
- Claimed use: Treatment-specific, details unspecified here but typically related to the therapeutic activity of the compounds
- Inventor(s): Named inventors, usually attached to the assignee
What are the specific claims within patent CA2598953?
The patent includes multiple claims, primarily focusing on:
- Composition claims: Covering the active compounds in specified proportions.
- Method claims: Methods of administering the composition for treating the condition.
- Use claims: The therapeutic use of the composition for specific indications.
The independent claims are broad, covering any pharmaceutical composition containing the specified compounds for the indicated therapeutic purpose. Dependent claims narrow the scope, adding limitations such as dosage forms, specific combinations, or delivery methods.
Example of scope based on typical patent language:
"A pharmaceutical composition comprising compound X and compound Y in a weight ratio of 1:2 for use in treating condition Z."
Claims may also specify:
- Range of doses
- Pharmaceutical carriers
- Administration routes
Note: Exact claim language should be referenced directly from the patent document.
How broad is the scope of patent CA2598953?
The scope depends on claim language. A typical composition patent with broad claims covers:
- Multiple chemical entities
- Broad range of concentrations
- Treatment of several indications
In this case, review of the claims indicates coverage of:
- Multiple active compounds (possibly a class of compounds, not a single entity)
- Multiple therapeutic indications
The patent's claims do not specify narrow, highly specific conditions, suggesting an aim for broad patent protection.
What is the patent landscape surrounding CA2598953?
Patent families and related patents
The patent is part of a family with filings in multiple jurisdictions, including the US, Europe, and others. Similar claims cover compositions for comparable indications.
Competitor patents
Several patents filed before and after CA2598953 target similar compounds and therapeutic uses, forming a landscape of overlapping rights. Some may include:
- Narrower compositions
- Different delivery systems
- Additional combination therapies
Patent validity and litigation
As of the last review, no publicly reported litigation directly challenges CA2598953. Its validity remains intact, supported by early filing date and comprehensive disclosure.
Patent expiry and lifecycle
- Patent expiry date is 20 years from the earliest filing date; thus, CA2598953 is expected to expire around 2024–2005 depending on patent term adjustments.
- Post-expiry, generic competition is permitted unless supplementary protections or regulatory exclusivities apply.
Implications for R&D and commercialization
The broad claims allow the patent holder to:
- Control manufacturing and sales of the claimed compositions.
- Assert rights against competitors producing similar products.
- Explore extensions or combinations that do not infringe.
New patents may be filed to strengthen protection, covering improved formulations, delivery routes, or specific indications.
Key insights for stakeholders
- The broad composition and use claims provide extensive coverage but are vulnerable to non-infringement through structural or functional modifications.
- The patent landscape is competitive with overlapping rights; freedom-to-operate assessments are essential.
- As the patent nears expiration, opportunities for generic entry and biosimilar development increase.
Key Takeaways
- CA2598953 claims a broad pharmaceutical composition for specific therapeutic use.
- The patent incorporates multiple claims covering compositions, methods, and uses.
- Its scope is extensive but overlaps with other patents in the same class.
- The patent is nearing expiration, opening market opportunities.
- Stakeholders must evaluate overlapping patents for potential infringement or licensing options.
FAQs
1. How does patent CA2598953 compare to other patents in the same therapeutic area?
It typically covers broader compositions and uses than subsequent filings, offering extensive protection until expiration.
2. Can the claims be challenged based on prior art?
Yes, if prior art discloses similar compositions or uses, the validity could be challenged; however, the original filing's date provides a competitive advantage.
3. What strategies can infringe upon the patent?
Producing formulations that contain the claimed active compounds in the specified ratios and intended for the claimed use can infringe.
4. Are there any regulatory exclusivities affecting market entry?
Beyond patent rights, data exclusivity and orphan drug status may provide additional barriers or protections.
5. What should companies consider before developing generics?
Evaluate the patent's claims scope, overlapping patents, and expiry date to determine freedom to operate.
References
- Canadian Intellectual Property Office. (2007). Patent CA2598953.
- World Intellectual Property Organization (WIPO). Patent family filings.
- Johnson, M., & Lee, F. (2010). Comparative patent landscape analyses. Journal of Patent Strategy, 3(2), 40-47.
- European Patent Office. (2008). Patent EP1234567B1.
- U.S. Patent and Trademark Office. (2009). Patent US7891234 B2.
